New genetic markers for transplant rejection

In cardiovascular, respiratory, kidney and haematological diseases transplantation remains the most effective long term therapy for patients with advanced organ failure. In addition, hematopoietic stem cell transplantation (HSCT) for the treatment of lymphoproliferative disorders and leukemias has recently become an important mainstay in oncology. There is an urgent need for non-invasive, predictive and diagnostic monitoring to improve outcomes. The global market for transplant diagnostics is projected to grow at 12% CAGR to reach $553 million in 2015.

Further Information: PDF

MBM ScienceBridge GmbH
Phone: (0551) 30724-151

Contact
Dr. Jens-Peter Horst

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Making diamonds at ambient pressure

Scientists develop novel liquid metal alloy system to synthesize diamond under moderate conditions. Did you know that 99% of synthetic diamonds are currently produced using high-pressure and high-temperature (HPHT) methods?[2]…

Eruption of mega-magnetic star lights up nearby galaxy

Thanks to ESA satellites, an international team including UNIGE researchers has detected a giant eruption coming from a magnetar, an extremely magnetic neutron star. While ESA’s satellite INTEGRAL was observing…

Solving the riddle of the sphingolipids in coronary artery disease

Weill Cornell Medicine investigators have uncovered a way to unleash in blood vessels the protective effects of a type of fat-related molecule known as a sphingolipid, suggesting a promising new…

Partners & Sponsors